


中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际  
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库



CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中国新药杂志



8  
2019  
Vol.28 | No.8

- 中药注射剂新药研发策略分析
- 从丁苯酞的成长历程看自主创新药的知识产权保护
- 抗肿瘤免疫检查点抑制剂的不良反应研究进展
- 拉西地平与苯磺酸氨氯地平治疗中老年轻中度原发性高血压的对比分析
- 从药物临床试验数据核查看申办者的职责履行情况

www.newdrug.cn

ISSN 1003-3734



万方数据

国家药品监督管理局主管



# 目次

半月刊 1992年创刊  
第28卷第8期 2019年4月30日出版

## •新药述评与论坛•

- 897 中药注射剂新药研发策略分析.....林红梅, 周刚, 王停  
903 从丁苯酞的成长历程看自主创新药的知识产权保护.....张溪, 李林, 周文婷  
908 血小板生成素受体激动剂avatrombopag的药理作用及临床评价.....于立婷, 刘娜, 史爱欣

## •重大新药创制专项巡礼•

- 913 山豆根醇沉物小鼠单次给药和大鼠重复给药28d毒性评价.....徐榛, 孙嘉彬, 邵珍, 等  
921 抗肿瘤免疫检查点抑制剂的不良反应研究进展.....钱仪敏, 李华, 马璟  
926 巴戟天寡糖对抑郁症患者血浆IL-6和TNF- $\alpha$ 的影响.....慕永刚, 邓翔, 张素贞, 等  
930 预防偏头痛新药降钙素基因相关肽单抗的临床研究进展.....侯敏, 陈剑鸿  
935 氟康唑共晶的晶体结构及Hirshfeld表面分析.....邢逞, 王雪, 胡堃, 等

## •生物医药前沿•

- 941 单克隆抗体药物临床前动物实验研究技术风险评估.....刘丹丹, 陈玉文

## •综述•

- 948 MAPK信号通路影响肿瘤多药耐药的研究进展.....柴冬亚, 袁佳琪, 周轶平  
954  $^{89}\text{Zr}$ 标记抗体PET显像技术在药物研发中的应用.....王燕, 杨敏, 缪丽燕  
961 抗疟疾药物的研究现状与发展.....汤雨晴, 郑维义

## •临床研究•

- 967 拉西地平与苯磺酸氨氯地平治疗中老年轻度原发性高血压的对比分析.....霍勇, 张慧敏, 葛均波, 等

## •药物临床试验核查专栏•

- 973 从药物临床试验数据核查看申办者的职责履行情况.....高荣, 王安娜, 唐静, 等

## •实验研究•

- 978 HPLC法同时测定加味肾康方颗粒中8种成分.....李雨珂, 谢文彬, 吴磊, 等  
984 柱切换-LC/MSn法快速推定注射用头孢美唑钠的杂质.....李进, 姚尚辰, 胡昌勤  
996 海松子提取物减轻阿尔茨海默病线虫A $\beta$ 毒性及机制探讨.....史涛涛, 罗世坚, 梁凤银, 等  
1001 两厂家两规格市售脂肪乳氨基酸(17)葡萄糖(11%)注射液的质量对比研究.....孙纯  
1008 头花蓼提取物在肾盂肾炎模型与正常大鼠体内的组织分布比较研究.....郑林, 陈浩, 孙慧园, 等  
1017 左卡尼汀通过改变小鼠乳酸和糖原含量延缓疲劳的实验研究.....栾海云, 杨清宝, 杨茗, 等

## •药物安全与合理应用•

- 1021 阿帕替尼不良反应3例及文献回顾.....谢燕瑾, 沈丽蓉, 陈玲, 等

[期刊基本参数] CN11-2850/R\*1992\*sm\*A4\*128\*zh\*P\*¥50.00\*\*21\*2019-04

责任编辑 赵文锐 英文审校 魏尔清 杜小莉 张鲸惊

- 897 Analysis of research and development strategy of new traditional Chinese medicine injections  
LIN Hong-mei, ZHOU Gang, WANG Ting
- 903 Viewing the intellectual property protection of independent innovative drugs from the growth process of butylphthalide  
ZHANG Xi, LI Lin, ZHOU Wen-ting
- 908 Pharmacological action and clinical evaluation of thrombopoietin receptor agonist avatrombopag  
YU Li-ting, LIU Yuan, SHI Ai-xin
- 913 Toxicity studies of alcohol precipitation from extracts of *Radix sophorae tonkinensis* after single dose administration in mice and 28 days repeated dose administration in rats  
XU Zhen, SUN Jia-bin, SHAO Zhen, *et al*
- 921 Advances in study on adverse reactions of anti-tumor immune checkpoint inhibitors  
QIAN Yi-min, LI Hua, MA Jing
- 926 Effects of *morinda officinalis* oligose on plasma IL-6 and TNF- $\alpha$  levels in patients with depression  
MU Yong-gang, DENG Shuo, ZHANG Su-zhen, *et al*
- 930 Advances in the monoclonal antibodies against calcitonin gene-related peptide for preventing migraine  
HOU Min, CHEN Jian-hong
- 935 Hirshfeld surface and structure analysis of co-crystal of fluconazole  
XING Cheng, WANG Xue, HU Kun, *et al*
- 941 Technical risk evaluation of the preclinical animal experiments of monoclonal antibody drugs  
LIU Dan-dan, CHEN Yu-wen
- 948 Research progress of MAPK signaling pathway for multidrug resistance in tumors  
CHAI Dong-ya, YUAN Jia-qi, ZHOU Yi-ping
- 954 Application of PET with  $^{89}\text{Zr}$  labeled antibodies in drug research and development  
WANG Yan, YANG Min, MIAO Li-yan
- 961 Research status and development of antimalarial drugs  
TANG Yu-qing, ZHENG Wei-yi
- 967 Antihypertensive effect and safety of lacidipine and amlodipine in middle-aged and elderly Chinese patients with mild-to-moderate essential hypertension  
HUO Yong, ZHANG Hui-min, GE Jun-bo, *et al*
- 973 Perspectives on the implementation of sponsors' responsibilities from the drug clinical trial data inspection  
GAO Rong, WANG An-na, TANG Jing, *et al*
- 978 Simultaneous determination of the contents of eight components in Jiawei Shengkangfang Granules by HPLC  
LI Yu-ke, XIE Wen-bin, WU Lei, *et al*
- 984 Rapid characterization of impurities in cefmetazole sodium for injection by online column-switching liquid chromatography tandem mass spectrometry  
LI Jin, YAO Shang-chen, HU Chang-qin
- 996 Extract of korean pine seed protects against  $\beta$ -amyloid toxicity in an Alzheimer disease model of *Caenorhabditis elegans*  
SHI Tao-tao, LUO Shi-jian, LIANG Feng-yin, *et al*
- 1001 Comparative study on the qualities of fat emulsion, amino acids (17) and glucose (11%) injections from two manufacturers  
SUN Chun
- 1008 Comparative study on tissue distribution of *Polygonum capitatum* extract between pyelonephritis model and normal rats  
ZHENG Lin, CHEN Hao, SUN Hui-yuan, *et al*
- 1017 Anti-fatigue effect of *L*-carnitine by changing lactic acid and glycogen contents in mice  
LUAN Hai-yun, YANG Qing-bao, YANG Ming, *et al*
- 1021 Three cases of adverse drug reactions induced by apatinib and literature review  
XIE Yan-jin, SHEN Li-rong, CHEN Ling, *et al*

Directed by: National Medical Products Administration

Sponsored by: China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association

Editor-in-Chief: SANG Guo-wei

Board Chairman: SHI Sheng-yi

Edited by: Editorial Board of Chinese Journal of New Drugs

Published by: Chinese Journal of New Drugs Co., Ltd.

Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China

Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>

E-mail: [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)

Printer: Beijing Kexin Printing Co., Ltd.

Domestic Distribution: Beijing Post Offices

Overseas Distribution: China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)

Domestic Subscription: Local Post Offices

Periodical Registration: ISSN 1003-3734 CN 11-2850/R

Publication Date: April 30, 2019

Copyright: 2019 by Chinese Journal of New Drugs Co., Ltd.





广告

# 艾瑞妮® 锐不可当 恒久爱她



- ✓ 小分子、不可逆酪氨酸激酶抑制剂
- ✓ HER2阳性乳腺癌晚期一线、二线患者皆可获益
- ✓ 联合卡培他滨治疗HER2阳性晚期乳腺癌II期研究，PFS达18.1个月
- ✓ 口服方便，一日一次

### 艾瑞妮® (马来酸吡咯替尼片) 简明处方资料

#### 【药品名称】

通用名称：马来酸吡咯替尼片  
英文名称：Pyrotinib Maleate Tablets  
商品名称：艾瑞妮®

#### 【适应症】

本品联合卡培他滨，适用于治疗表皮生长因子受体2 (HER2) 阳性、既往未接受或接受过曲妥珠单抗的复发或转移性乳腺癌患者。使用本品前患者应接受过蒽环类或紫杉类化疗。

#### 【用法用量】

吡咯替尼推荐剂量为400mg，每日1次，餐后30分钟内口服，每天同一时间服药。连续服用，每21天为一个周期。如果患者漏服了某一天的吡咯替尼，不需要补服，下一次按计划服药即可。

卡培他滨的推荐剂量为1000mg/m<sup>2</sup>，每日2次口服（早晚各1次，每日总剂量2000mg/m<sup>2</sup>），在餐后30分钟内服用（早上一次与吡咯替尼同服），连续服用14天休息7天，每21天为一个周期。有关卡培他滨用药的详细信息，请参见卡培他滨的药品说明书。

治疗用药应持续直到疾病进展或出现不能耐受的毒性反应。

#### 【不良反应】

腹泻、手足综合征、呕吐、白细胞计数降低、中性粒细胞计数降低、恶心、食欲下降等。

#### 【规格】

按C<sub>15</sub>H<sub>11</sub>ClN<sub>6</sub>O<sub>3</sub>计 (1) 80 mg; (2) 160 mg。

#### 【禁忌】

已知对吡咯替尼或本品任何成份过敏者禁用。

#### 【批准文号】

160mg：国药准字 H20180012  
80mg：国药准字 H20180013

完整资料详见产品说明书

仅供医学、药学专业人士阅读，仅限医学、药学专业刊物发表。

苏药广审(文)第2018090626号

